These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 7638130)

  • 1. [Symptomatic relief of carcinoid syndrome by ketanserin. A case].
    Luzzatto G; Pozza M; Cella G
    Presse Med; 1995 May; 24(19):897-9. PubMed ID: 7638130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carcinoid syndrome and serotonin: therapeutic effects of ketanserin.
    Robertson JI
    Cardiovasc Drugs Ther; 1990 Jan; 4 Suppl 1():53-8. PubMed ID: 2285651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ketanserin, a 5-HT antagonist, in symptomatic treatment of carcinoid syndrome.
    Sullivan PA; O'Donovan M
    Ir J Med Sci; 1986 Dec; 155(12):436. PubMed ID: 3818255
    [No Abstract]   [Full Text] [Related]  

  • 4. The pentagastrin test in the diagnosis of the carcinoid syndrome. Blockade of gastrointestinal symptoms by ketanserin.
    Ahlman H; Dahlström A; Grönstad K; Tisell LE; Oberg K; Zinner MJ; Jaffe BM
    Ann Surg; 1985 Jan; 201(1):81-6. PubMed ID: 2578277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ketanserin versus placebo in carcinoid syndrome. A clinical controlled trial.
    Gustafsen J; Lendorf A; Raskov H; Boesby S
    Scand J Gastroenterol; 1986 Sep; 21(7):816-8. PubMed ID: 3535008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carcinoid syndrome: comparison of pretreatment regimes in the same patient.
    Padfield NL
    Ann R Coll Surg Engl; 1987 Jan; 69(1):16-7. PubMed ID: 2952043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study.
    Ruszniewski P; Valle JW; Lombard-Bohas C; Cuthbertson DJ; Perros P; Holubec L; Delle Fave G; Smith D; Niccoli P; Maisonobe P; Atlan P; Caplin ME;
    Dig Liver Dis; 2016 May; 48(5):552-558. PubMed ID: 26917486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Symptomatic treatment of the malignant carcinoid syndrome with octreotide].
    Alberts AS; Falkson G
    S Afr Med J; 1989 Jan; 75(1):30-1. PubMed ID: 2911781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carcinoid syndrome. Medical management.
    Clarke B; Hodgson HJ
    Br J Hosp Med; 1986 Mar; 35(3):146-8, 150, 152. PubMed ID: 3742126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of carcinoid syndrome with a somatostatin analogue].
    Döbrönte Z; Stöckert A; Végh G; Varga L
    Orv Hetil; 1992 Mar; 133(12):731-4. PubMed ID: 1372969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel).
    Khan MS; El-Khouly F; Davies P; Toumpanakis C; Caplin ME
    Aliment Pharmacol Ther; 2011 Jul; 34(2):235-42. PubMed ID: 21585408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Skin manifestations in carcinoid syndrome. Serotonin-producing carcinoid tumour of the ileum with liver metastases and flushing of the skin. Report of a case with cutaneous symptoms only.
    WEREIDE K; NESET G
    Acta Derm Venereol; 1961; 41():264-76. PubMed ID: 13784412
    [No Abstract]   [Full Text] [Related]  

  • 13. The pentagastrin test in the diagnosis of the carcinoid syndrome.
    Ahlman H; Dahlström A; Grönstad K; Jaffe BM; Nilsson O; Oberg K
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S86-8. PubMed ID: 2412067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of octreotide on basal and stimulated hormone levels in patients with carcinoid syndrome.
    Oberg K; Norheim I; Theodorsson E; Ahlman H; Lundqvist G; Wide L
    J Clin Endocrinol Metab; 1989 Apr; 68(4):796-800. PubMed ID: 2466045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The control of flushing and diarrhoea in carcinoid syndrome by an antiserotonin agent, BC105.
    Loong SC; Lance JW; Rawle KC
    Med J Aust; 1968 Nov; 2(19):845-8. PubMed ID: 5728213
    [No Abstract]   [Full Text] [Related]  

  • 16. [Effects of the administration of somatostatin 14 in the carcinoid syndrome. Clinical and biological study of 2 cases].
    Guillard JF; Galmiche JP; Chayvialle JA; Kremer M; Comoy E; Lerebours E; Charbonnel B; Colin R
    Gastroenterol Clin Biol; 1983 Dec; 7(12):1016-22. PubMed ID: 6141119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide.
    Ruszniewski P; Ish-Shalom S; Wymenga M; O'Toole D; Arnold R; Tomassetti P; Bax N; Caplin M; Eriksson B; Glaser B; Ducreux M; Lombard-Bohas C; de Herder WW; Delle Fave G; Reed N; Seitz JF; Van Cutsem E; Grossman A; Rougier P; Schmidt W; Wiedenmann B
    Neuroendocrinology; 2004; 80(4):244-51. PubMed ID: 15627802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Collision adenoma-carcinoid tumour of the colon complicated by carcinoid syndrome.
    Hui CK
    Singapore Med J; 2012 Sep; 53(9):e195-7. PubMed ID: 23023914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A prolonged-action somatostatin analog and carcinoid syndrome].
    Chayvialle JA
    Bull Acad Natl Med; 1989 May; 173(5):643-50; discussion 650-1. PubMed ID: 2478266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of ondansetron on gastrointestinal symptoms in carcinoid syndrome.
    Wymenga AN; de Vries EG; Leijsma MK; Kema IP; Kleibeuker JH
    Eur J Cancer; 1998 Jul; 34(8):1293-4. PubMed ID: 9849494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.